Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Dose-Ranging Study of Novel Anticoagulant Promising
Link ID 8438
Title Dose-Ranging Study of Novel Anticoagulant Promising
Url http://www.medscape.com/viewarticle/580131?src=rss
Description The addition of apixaban to antiplatelet therapy resulted in an increase in bleeding, but there was also an observed trend toward a reduction in clinically relevant ischemic events, a new dose-ranging study has shown. Heartwire
Category Articles > Cardiology
Keywords
Date Sep 6, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Cardiology
1. Smoke-Free Policies Bring Health Benefits
  The International Agency for Research on Cancer has announced that the implementation of smoke-free policies in many Western countries has reduced the prevalence of smoking and had subsequent health benefits. Heartwire
Category:   Articles > Cardiology


2. Phase 2 Study Shows Thyroid Mimetic Reduces Cholesterol Levels Without Adverse Cardiac Effects
  The drug, known as KB2115, cut LDL- and total-cholesterol levels 40% over a two-week period without any adverse cardiovascular effects, a previous concern for researchers, as thyroid hormones administered in high levels can have deleterious effects on the heart. Heartwire
Category:   Articles > Cardiology


3. BRIEF-PCI: Infusion of Eptifibatide Can Be Shortened
  A shortened, two-hour infusion of the GP IIb/IIIa inhibitor eptifibatide following nonemergency PCI is just as effective as the standard 18-hour infusion of the drug and is probably safer, according to a new study. Heartwire
Category:   Articles > Cardiology


4. ENHANCE Results Yield Disappointment for Ezetimibe
  The results of the long-awaited and controversial ENHANCE trial, finally announced today, have shown no benefit of the combination of ezetimibe and simvastatin over simvastatin alone. Heartwire
Category:   Articles > Cardiology


5. BART Closes the Book on Aprotinin
  Results from the trial--halted last year due to safety concerns--clearly point to increased deaths in high-risk CABG patients randomized to aprotinin instead of a lysine-analog antifibrinolytic. Heartwire
Category:   Articles > Cardiology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS